BioSpace News Archive

Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today presented initial results from Phase 1 of its ongoing evaluation of HMB-001.

Precision BioSciences, Inc. today announced that its Board of Directors has approved a 1-for-30 reverse stock split of the Company’s common stock.

Evoke Pharma, Inc. announced today that it has priced an underwritten public offering led by Nantahala Capital Management, with participation by other fundamental investors, for gross proceeds of up to $30 million, that includes initial upfront funding of approximately $7.5 million, prior to deducting underwriting discounts and commissions and estimated offering expenses.

Humacyte, Inc. (Nasdaq: HUMA) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to Humacyte’s Biologics License Application (BLA) seeking approval of the Human Acellular Vessel (HAV) in urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and when autologous vein use is not feasible.

Nuvectis Pharma, Inc. today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences.

Quantum-Si Incorporated today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, February 29, 2024.

PharmAla Biotech Holdings Inc. is pleased that it has entered into a consulting relationship with Red Light Holland Corp. (“ Red Light ”), (CSE: TRIP) to consult on the development of clinical-grade Psilocybin Drug Product extracted from Red Light Holland’s mushroom portfolio.

NRx Pharmaceuticals, Inc. today announced that its Asia Pacific strategic partner Lotus Pharmaceutical Co. Ltd (1975.TW) identified enrollment completion of the NRx clinical trial in bipolar depression as a material event in is February 7 financial filing.

Intelligent Bio Solutions Inc. today announced its financial results for fiscal second quarter and six months ended December 31, 2023, and provided a business update.

CooperSurgical today announced that they have partnered to offer families of Cord Blood Registry® (CBR®) exclusive newborn genetic screening panels.